Gabapentin NDC 0121-2134

NDC codes

FDA NDC Directory

Product NDC (as listed)0121-2134Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00121-2134Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0121-2134-40	00121213440	4 TRAY in 1 CASE (0121-2134-40) / 10 CUP, UNIT-DOSE in 1 TRAY / 6 mL in 1 CUP, UNIT-DOSE (0121-2134-06)Marketed from Jun 12, 2025

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Gabapentin
Generic name (nonproprietary): gabapentin
Active ingredients: Gabapentin — 250 mg/5mL
Dosage form: Solution
Route: Oral
Labeler: PAI Holdings, LLC dba PAI Pharma
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211330
Marketing start: Jun 12, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0121-2134_01ef9bd4-78c9-4ec7-8633-c4e0260ad2deSPL ID 01ef9bd4-78c9-4ec7-8633-c4e0260ad2deSPL set ID 6d3fd1f9-c831-4262-af10-291838a53541RxCUI 283523UNII 6CW7F3G59X

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400121213440 followed by a unit qualifier and the quantity

Package 00121-2134-40. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 31, 2025.

Indications (excerpt from the label)

Gabapentin oral solution is indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin is indicated for: Postherpetic neuralgia in adults ( 1 ) Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211330

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211330
Product	Strength	Form · route	Labeler	Product NDC
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	PAI Holdings, LLC dba PAI Pharma	0121-1067
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	American Health Packaging	60687-919
Gabapentin	Gabapentin 250 mg/5mL	SolutionOral	PAI Holdings, LLC dba PAI Pharma	0121-4067